OTLK Outlook Therapeutics Inc.

2.05
+0.04  (+2%)
Previous Close 2.01
Open 2.09
Price To Book -1.61
Market Cap 45,304,241
Shares 22,099,630
Volume 20,670
Short Ratio
Av. Daily Volume 5,957,683

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial 85% enrolled as of May 15, 2019. Data likely around mid-2020.
ONS-5010-001
Wet age-related macular degeneration (wet AMD)
Phase 3 dosing to commence June 2019.
ONS-5010-002
Wet age-related macular degeneration (wet AMD)

Latest News

  1. Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD
  2. Hottest Wall Street Stories: What's Up, What's Down
  3. Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010
  4. A Look At Benzinga Pro's Most-Searched Tickers For May 24
  5. Outlook Therapeutics stock rockets on heavy volume again, set to triple in 3 days
  6. Outlook Therapeutics Rallies 150% In 2 Days: What You Need To Know
  7. Outlook Therapeutics' stock rockets on heavy volume again, has more than doubled in 2 days
  8. Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer
  9. Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019
  10. Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development
  11. Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
  12. Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010
  13. Outlook Therapeutics Announces Reverse Stock Split
  14. Outlook Therapeutics Regains Compliance With All Nasdaq Listing Requirements
  15. Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA
  16. Outlook Therapeutics Provides Business Update and Reports First Quarter Financial Results for Fiscal 2019
  17. Healthcare Investment Opportunities You Can't Miss
  18. Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
  19. Outlook Therapeutics Announces Exercise Price Reduction and Term Extension of Series A Warrants
  20. Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement